190 related articles for article (PubMed ID: 2544491)
1. Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, dactinomycin, vincristine, and cyclophosphamide.
Gallion HH; van Nagell JR; Donaldson ES; Higgins RV
Gynecol Oncol; 1989 Jul; 34(1):98-100. PubMed ID: 2544491
[TBL] [Abstract][Full Text] [Related]
2. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
Surwit EA; Childers JM
J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
[TBL] [Abstract][Full Text] [Related]
3. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Holden L
Br J Obstet Gynaecol; 1991 Jun; 98(6):550-7. PubMed ID: 1651757
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
[TBL] [Abstract][Full Text] [Related]
5. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
[TBL] [Abstract][Full Text] [Related]
6. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984).
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Holden L; Dent J
Br J Obstet Gynaecol; 1986 Jan; 93(1):63-9. PubMed ID: 3002420
[TBL] [Abstract][Full Text] [Related]
7. Metastatic placental site trophoblastic tumor. Report of a case with complete response to chemotherapy.
Mangili G; Garavaglia E; De Marzi P; Zanetto F; Taccagni G
J Reprod Med; 2001 Mar; 46(3):259-62. PubMed ID: 11304870
[TBL] [Abstract][Full Text] [Related]
8. Management of resistant gestational trophoblastic tumors.
Newlands ES; Bower M; Holden L; Short D; Seckl MJ; Rustin GJ; Begent RH; Bagshawe KD
J Reprod Med; 1998 Feb; 43(2):111-8. PubMed ID: 9513872
[TBL] [Abstract][Full Text] [Related]
9. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
10. Management of high-risk gestational trophoblastic disease.
Lurain JR
J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of gestational trophoblastic disease at a single institute.
Alici S; Eralp Y; Saip P; Argon A; Basaran M; Topuz E; Aydiner A
Tohoku J Exp Med; 2002 Jun; 197(2):95-100. PubMed ID: 12233789
[TBL] [Abstract][Full Text] [Related]
12. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
[TBL] [Abstract][Full Text] [Related]
13. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.
Al-Husaini H; Soudy H; Darwish A; Ahmed M; Eltigani A; Edesa W; Elhassan T; Omar A; Elghamry W; Al-Hashem H; Al-Hayli S; Madkhali I; Ahmad S; Al-Badawi IA
Clin Transl Oncol; 2015 May; 17(5):409-15. PubMed ID: 25398721
[TBL] [Abstract][Full Text] [Related]
14. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
Kohorn EI
Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
[TBL] [Abstract][Full Text] [Related]
15. Gestational trophoblastic disease presenting as a large metastasis to the finger.
Hetzel DJ; Olt GJ; Sorosky JI; Mortel R; Singapuri K; Podczaski ES
Gynecol Oncol; 1996 Oct; 63(1):123-6. PubMed ID: 8898181
[TBL] [Abstract][Full Text] [Related]
16. Successful resolution of persistent trophoblastic disease after partial mole with the EMA-CO regimen.
Dgani R; Zalel Y; Biran H; Blickstein I; Caspi B; Weissman A; Shoham Z
Eur J Obstet Gynecol Reprod Biol; 1994 Mar; 54(1):77-9. PubMed ID: 7519153
[TBL] [Abstract][Full Text] [Related]
17. High-risk gestational trophoblastic neoplasia at Gujarat Cancer and Research Institute: thirteen years of experience.
Chauhan A; Dave K; Desai A; Mankad M; Patel S; Dave P
J Reprod Med; 2010; 55(7-8):333-40. PubMed ID: 20795348
[TBL] [Abstract][Full Text] [Related]
18. Update in cancer chemotherapy: genitourinary tract cancer, Part 7: Gestational trophoblastic neoplasms.
Wright JC
J Natl Med Assoc; 1988 Jul; 80(7):753-61. PubMed ID: 2841462
[TBL] [Abstract][Full Text] [Related]
19. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
20. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy.
Cyriac S; Rajendranath R; Sridevi V; Sagar TG
J Reprod Med; 2011; 56(5-6):219-23. PubMed ID: 21682117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
